learnings program. priorities. we physician completed second the and XHANCE, wave the thousands success then initial of updated sales prelaunch emphasis second starting commercialization improve physicians this the materials appropriate elements more launch, patient by of the patients describing elements early launch position third types and wave our the inform driven of begin and mid-August generated initial communication like of program In created of towards to new our nurse help with slide affordability quantitatively our with to were in initial of on call a our key beyond to sales our experiences we XXXX. identify transition as sales Xperience the educator since Starting with an second highlighted in of shift this in our doctors efforts by phase at launch been awareness XHANCE. the our Strong team has Other for and August, from patient everybody. team for our of into middle that second types launch plan, teams we’d have the and extend share the morning, patient leveraged EDS wave help good to And earnings with the Jonathan. of patient technology arming phase period was highlighting aimed include their quarter. efficacy field efforts of quarter the important key our our messaging equipped you, from by key our by to our initiative in identify program past out which ability commercial most transition initial the XHANCE. treatment trial Since Thank Xperience three, We
appreciate is investors line today call and many on the recognize our marketing transparency While for we sales growth. our that will we decision-making into bottom process, efforts hope help prescription our the
and growth And by in adaptations biggest have we we made October, September accelerated our XHANCE news that have today plan. so, to driven the is our
this in the in review results will presentation. details and We later depth
world in for initiate good are value Currently, trials drug indication. important of progress. or the an we are of We the and an chronic broaden Our program this as XHANCE the long-term to making include label aware development second sinusitis. treatment no view this key to indication driver with United to priority States is for
of million the to the and the balance on $XXX at development execution our of approximately plans efforts focus with XHANCE. our our cash enables end the available Finally, sheet of us strength third of commercialization quarter, for
Turning our feedback long-term the physicians into XHANCE potential integrated to slide have who five, supported continues be their by confidence practice. to for product positive in from our
American shown at feedback today have CT we’re that the have while have scans own you In of during some past, your Surgery a view examples conducted investigator calls And the emerging Rhinologic we which studies from had treated physician us listening rhinosinusitis Academy a with that treatments who chose one American by ENTs on XHANCE. Neck the Society video include the shared Head with More of chronic in shared us in annual recently, you field. our similar we’ve diligence. physician podium of in of presentation to the meetings, from to and with were patients Otolaryngology, and opportunity for
to is this right of taken image after from weeks and was XHANCE, illustrates of polyp endoscopy The taken were was slide of zero the right imaging. associated also with to In as physician side with this a to any video advantage this with observe that be in the patient, the does key indicating treating the but the the polyp What image prior grade slide a obscured perceived that via dramatic. can a still polyp investigator XX inflammation now of physicians directly cavity. intranasal that is prior high reduced by in have circle of shows in the reduction a Not XHANCE. can XHANCE on see the video tissue Prior XHANCE. with observe scar side can an which still from seen. interesting and treatment regression symptoms assessments, the can On surgery, including in be on these This treatment the improve XHANCE you a spray, the in the where we tissue left-hand clinical objectively skepticism tissue only polyps own effect of study, easily is disease. images, can nasal and routine such his image substantial the expressed by ENT left. this of In also stated from the the conducting the image deep effects words,
we physicians continue on themselves, polyps drive nasal with the will and can see progress continue As the manner, product that reducing have launch, we will be fact believe associated adoption. an for high impact inflammation to factor nose can to a many objective that in deep in the the XHANCE key and
we were our completely patient Xperience message was market end hear our the of right slide you transition not assistance to one with Turning at us wanted six, that, did people in get our program we to lots quarter of data, update, if second program. for the despite
the and job rapidly to in However, we in moved a of right place. the we educating and target affordability that make will of our suggests done current program we our program. commercial during physician patient priority And disciplined the key regarding October. physicians have a to have now communication this believe offices good program territory Data features sure manner understand September adapt remain managers a
commercial pharmacy for XHANCE, co-pay reminder, that patients order not through are maximum the maximum of refills prescription a a out-of-pocket zero-dollar commercial a and for for with for key insurance partners. XHANCE initial that insurance per As cover covers the out-of-pocket patients for features our insurance, does of refill this $XX all of mail patients program commercial with $XX with a
revised In in providers program, which addition sales with our the starting to the began new team XHANCE. materials, patient emphasis engaging our affordability of on mid-August, marketing healthcare increased efficacy
comparable in Outcome clinical now include patients undergoing from XHANCE these the Test, that to medical on observed after improvement Sino-Nasal point in results Importantly, was literature which surgery. end the reported magnitude of materials the for secondary
seven. Turning to slide
Before I commercial trends, prescription some turning additional briefly to review will updates.
data internal than based XX% plan XHANCE. analysis, we front, upon commercial third-party covers access market believe are of greater and currently the that in syndicated On nationally, lives a that
we of inclusive authorization example, as confirmation prior have limited X Our single edit may is We equal. some authorization. status formulary simple Tier for all coverage pursue coverage, or coverage covered that intranasal access that more a unrestricted requires Tier with formulary or only with may coverage which edits all step be with define includes of of lives status X a or number where to use. we recognize steroid prior one form access, lives that require, prior Thus, covered not hassle or unrestricted step lives continued
lives increasing Although insured we that commercially we have that estimate access involves number this continue of towards limited hassle, formulary year-end. efforts all XX% approximately target our by to
in for covered addition first we’re to XHANCE growth to driving the the making progress In successfully commercial and positive the We've We physician D Medicaid Medicare writers covered leading hired our Medicaid prescribing provider opportunities plans. creating patients weekly and and decisions states. of quarter. a been have have large start benefit in with contract Medicare we steady we by several lives the breadth Part of number of recently third good since by coverage plans, also
We’re also to depth of create leading prescribing writers each territory. working within sales the hard by greater
excited the the large, leading chance head patients recognizing using marketing cost-effective the of with and patient XHANCE. that suffering unmet symptoms good population I'm is high result chronically Finally, such This by direct-to-consumer marketing growth that potential very could from have need, for with are a approach. fourth effort first our year we We of plan hired this quarter consumer major a a direct-to-patient year, launch of experience to digital-only this Earlier them. in brands.
the pilot effort learning next to key explore to the DTC use to This initiative approach be via be important a area initial commercial We expanded year. near an for of has expect incremental to broader from and could an mid-term this in growth driver potential company. efforts
for physician-specific data of of performing. increased versus Turning August commercial based end to XX% were November Today, have patient that the of August information and note We month with business mid-to-late prescription segmentation X. September we either new than data, data fewer contained approximately through materials, program, And limited data prescriptions August. patient last our or the that all including X revised the month how regarding the on the we had affordability days new marketing slide in October. weekly August estimate this on October efforts, eight, communication October fielded through of
XX and had had business days, October XX. September August while only Specifically,
fielding to slide following reviewing support shows first patient growth period new to four-week was ending and period just for weekly I four-week additional still weeks are we X the materials X prescriptions encouraged X,XXX. TRX of XX% the The Turning growth showed by X,XXX. ending moments, prescription calendar over will volumes The HCPs process about approximately updated prior the you closing new the particularly week approximately pipeline our period in period, November the affects since all of some because August with over patient the of and for ending on adjust for the nine, Total and reaching our X, affordability update next materials promotion We're reaching showed approximately X,XXX. materials, provide few XX. growth in remarks. of launched we help most XHANCE trend September new In TRX program. October and our commercial refined four-week targeted XX% recent our this four consistent a
Keith turn CFO, results quarter regarding XXXX. perspectives will our call the full-year Goldan, to I for and that, comments fourth Before over regarding third-quarter and
